PExA Past Earnings Performance
Past criteria checks 0/6
PExA's earnings have been declining at an average annual rate of -0.7%, while the Life Sciences industry saw earnings growing at 30.7% annually. Revenues have been growing at an average rate of 7.8% per year.
Key information
-0.7%
Earnings growth rate
27.0%
EPS growth rate
| Life Sciences Industry Growth | 31.8% |
| Revenue growth rate | 7.8% |
| Return on equity | -60.8% |
| Net Margin | -399.1% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How PExA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -8 | 9 | 0 |
| 30 Sep 23 | 4 | -6 | 9 | 0 |
| 30 Jun 23 | 6 | -4 | 9 | 0 |
| 31 Mar 23 | 6 | -4 | 9 | 0 |
| 31 Dec 22 | 6 | -4 | 9 | 0 |
| 30 Sep 22 | 4 | -5 | 9 | 0 |
| 30 Jun 22 | 2 | -8 | 8 | 0 |
| 31 Mar 22 | 2 | -7 | 8 | 0 |
| 31 Dec 21 | 2 | -8 | 8 | 0 |
| 30 Sep 21 | 2 | -9 | 8 | 0 |
| 30 Jun 21 | 2 | -8 | 8 | 0 |
| 31 Mar 21 | 1 | -8 | 7 | 0 |
| 31 Dec 20 | 1 | -8 | 7 | 0 |
| 30 Sep 20 | 1 | -8 | 8 | 0 |
| 30 Jun 20 | 1 | -8 | 8 | 0 |
| 31 Mar 20 | 1 | -9 | 8 | 0 |
| 31 Dec 19 | 4 | -6 | 8 | 0 |
| 30 Sep 19 | 5 | -5 | 8 | 0 |
| 30 Jun 19 | 5 | -4 | 7 | 0 |
| 31 Mar 19 | 5 | -4 | 7 | 0 |
| 31 Dec 18 | 3 | -6 | 7 | 0 |
| 30 Sep 18 | 2 | -6 | 6 | 0 |
| 30 Jun 18 | 2 | -5 | 6 | 0 |
| 31 Mar 18 | 2 | -6 | 5 | 0 |
| 31 Dec 17 | 2 | -5 | 5 | 0 |
| 30 Sep 17 | 3 | -6 | 7 | 0 |
| 30 Jun 17 | 4 | -4 | 7 | 0 |
| 31 Mar 17 | 4 | -4 | 7 | 0 |
| 31 Dec 16 | 4 | -3 | 8 | 0 |
| 30 Sep 16 | 4 | -3 | 4 | 0 |
| 30 Jun 16 | 3 | -4 | 3 | 0 |
| 31 Mar 16 | 3 | -3 | 2 | 0 |
| 31 Dec 15 | 3 | -3 | 1 | 0 |
| 30 Sep 15 | 1 | -1 | 0 | 0 |
| 30 Jun 15 | 1 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Quality Earnings: PEXA B is currently unprofitable.
Growing Profit Margin: PEXA B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PEXA B is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare PEXA B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEXA B is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (46.4%).
Return on Equity
High ROE: PEXA B has a negative Return on Equity (-60.83%), as it is currently unprofitable.